LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ONCO
Onconetix, Inc.
There isn't enough reported data to score ONCO yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ONCO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ONCO's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ONCO PE Valuation
ONCO has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ONCO Forward outlook
There aren't enough analyst estimates for ONCO to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus ONCO down 117%.
ONCO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$766,680.00 | +$3,828,845.00 |
| Q2 2025 | -$888,080.00 | +$4,109,920.00 |
| Q1 2025 | -$1,973,700.00 | +$2,293,300.00 |
| Q4 2024 | -$2,801,175.00 | +$921,825.00 |
| Q3 2024 | -$4,595,525.00 | -$2,923,041.56 |
| Q2 2024 | -$4,998,000.00 | -$3,393,516.56 |
| Q1 2024 | -$4,267,000.00 | -$2,407,516.56 |
| Q4 2023 | -$3,723,000.00 | -$1,853,000.00 |
ONCO is still losing money, but far less than before: $766,680.00 per share over the past year, against $4,998,000.00 at its worst in mid-2024.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ONCO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ONCO on profitability, with a higher operating margin.
ONCO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $17.1K | -84% |
| Q1 2026 | $21.5K | -79% |
| Q4 2025 | $303.6K | -57% |
| Q3 2025 | $303.7K | -25% |
| Q2 2025 | $106.5K | -85% |
| Q1 2025 | $101.6K | -75% |
ONCO's revenue has slid since its 2024 peak: $17,120 last quarter, down 84% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -15951% | -14134 points |
| Q1 2026 | -47657% | -35288 points |
| Q4 2025 | -422% | +3672 points |
| Q3 2025 | -681% | -31 points |
| Q2 2025 | -1817% | +114 points |
| Q1 2025 | -12369% | -9599 points |
| Q4 2024 | -4094% | N/A |
| Q3 2024 | -650% | N/A |
ONCO's operating margin was −15951% last quarter, down 14133 points from the same quarter a year ago, near the bottom of its range since 2024.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with ONCO at up 49%.
ONCO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$921.5K | +$3.4M |
| Q3 2024 | -$1.1M | +$1.9M |
| Q2 2024 | -$3.2M | -$1.4M |
| Q1 2024 | -$5.2M | -$788.7K |
| Q4 2023 | -$4.3M | -$1.5M |
| Q3 2023 | -$3M | -$1.2M |
| Q2 2023 | -$1.8M | +$1.4M |
| Q1 2023 | -$4.4M | -$3.6M |
ONCO has burned cash in almost every quarter: −$6M over the past year, against −$16M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ONCO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ONCO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3468% | +218K shares |
| 1 year | +52301% | +224K shares |
| 3 years | +3203857% | +224K shares |
ONCO has 224,277 diluted shares, up 52301% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2023 | $25,527 |
| Q1 2023 | $33,454 |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ONCO Net Leverage
ONCO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ONCO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.5 | Oversold |
| Stochastic | 17.9 | Oversold |
ONCO's weekly RSI is 29 (oversold) and its Stochastic is 18 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ONCO PE vs Healthcare Sector
ONCO has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ONCO on trend strength, trading above more of its moving averages.
ONCO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.05 | 50% below |
| 20 week MA | $7.26 | 58% below |
| 50 week MA | $229.4 | 99% below |
| 100 week MA | $3,385.0 | 100% below |
| 200 week MA | $414,179.2 | 100% below |
ONCO is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ONCO on returns for 2026, with the stronger performance.
ONCO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $97,580,000.0 | $1,751,000.0 | -98% |
| 2023 | $1,751,000.0 | $336,600.0 | -81% |
| 2024 | $336,600.0 | $16,365.1 | -95% |
| 2025 | $16,365.1 | $715.0 | -96% |
| 2026 YTD | $715.0 | $3.03 | -100% |
ONCO has finished every year since 2022 lower, and it's down 100% so far in 2026.